Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
Multiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasm...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0210407 |
id |
doaj-fce162ac7b7543709c293bcf121e8100 |
---|---|
record_format |
Article |
spelling |
doaj-fce162ac7b7543709c293bcf121e81002021-03-03T20:59:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021040710.1371/journal.pone.0210407Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.Nicole BrennerAlexander J MentzerJulia ButtKathrin L BrabandAngelika MichelKatie JefferyPaul KlenermanBarbara GärtnerPaul SchnitzlerAdrian HillGraham TaylorMaria A DemontisEdward GuyStephen J HadfieldRachael AlmondNaomi AllenMichael PawlitaTim WaterboerMultiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasma gondii (T. gondii) were developed and validated against established reference assays. For each pathogen, between 3 and 5 specific antigens were recombinantly expressed as GST-tag fusion proteins in Escherichia coli and tested in Monoplex Serology, i.e. assays restricted to the antigens from one particular pathogen. For each of the four pathogen-specific Monoplex assays, overall seropositivity was defined using two pathogen-specific antigens. In the case of HBV Monoplex Serology, the detection of past natural HBV infection was validated based on two independent reference panels resulting in sensitivities of 92.3% and 93.0%, and specificities of 100% in both panels. Validation of HCV and HTLV-1 Monoplex Serology resulted in sensitivities of 98.0% and 95.0%, and specificities of 96.2% and 100.0%, respectively. The Monoplex Serology assay for T. gondii was validated with a sensitivity of 91.2% and specificity of 92.0%. The developed Monoplex Serology assays largely retained their characteristics when they were included in a multiplex panel (i.e. Multiplex Serology), containing additional antigens from a broad range of other pathogens. Thus HBV, HCV, HTLV-1 and T. gondii Monoplex Serology assays can efficiently be incorporated into Multiplex Serology panels tailored for application in seroepidemiological studies.https://doi.org/10.1371/journal.pone.0210407 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nicole Brenner Alexander J Mentzer Julia Butt Kathrin L Braband Angelika Michel Katie Jeffery Paul Klenerman Barbara Gärtner Paul Schnitzler Adrian Hill Graham Taylor Maria A Demontis Edward Guy Stephen J Hadfield Rachael Almond Naomi Allen Michael Pawlita Tim Waterboer |
spellingShingle |
Nicole Brenner Alexander J Mentzer Julia Butt Kathrin L Braband Angelika Michel Katie Jeffery Paul Klenerman Barbara Gärtner Paul Schnitzler Adrian Hill Graham Taylor Maria A Demontis Edward Guy Stephen J Hadfield Rachael Almond Naomi Allen Michael Pawlita Tim Waterboer Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. PLoS ONE |
author_facet |
Nicole Brenner Alexander J Mentzer Julia Butt Kathrin L Braband Angelika Michel Katie Jeffery Paul Klenerman Barbara Gärtner Paul Schnitzler Adrian Hill Graham Taylor Maria A Demontis Edward Guy Stephen J Hadfield Rachael Almond Naomi Allen Michael Pawlita Tim Waterboer |
author_sort |
Nicole Brenner |
title |
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. |
title_short |
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. |
title_full |
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. |
title_fullStr |
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. |
title_full_unstemmed |
Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. |
title_sort |
validation of multiplex serology for human hepatitis viruses b and c, human t-lymphotropic virus 1 and toxoplasma gondii. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2019-01-01 |
description |
Multiplex Serology is a high-throughput technology developed to simultaneously measure specific serum antibodies against multiple pathogens in one reaction vessel. Serological assays for hepatitis B (HBV) and C (HCV) viruses, human T-lymphotropic virus 1 (HTLV-1) and the protozoan parasite Toxoplasma gondii (T. gondii) were developed and validated against established reference assays. For each pathogen, between 3 and 5 specific antigens were recombinantly expressed as GST-tag fusion proteins in Escherichia coli and tested in Monoplex Serology, i.e. assays restricted to the antigens from one particular pathogen. For each of the four pathogen-specific Monoplex assays, overall seropositivity was defined using two pathogen-specific antigens. In the case of HBV Monoplex Serology, the detection of past natural HBV infection was validated based on two independent reference panels resulting in sensitivities of 92.3% and 93.0%, and specificities of 100% in both panels. Validation of HCV and HTLV-1 Monoplex Serology resulted in sensitivities of 98.0% and 95.0%, and specificities of 96.2% and 100.0%, respectively. The Monoplex Serology assay for T. gondii was validated with a sensitivity of 91.2% and specificity of 92.0%. The developed Monoplex Serology assays largely retained their characteristics when they were included in a multiplex panel (i.e. Multiplex Serology), containing additional antigens from a broad range of other pathogens. Thus HBV, HCV, HTLV-1 and T. gondii Monoplex Serology assays can efficiently be incorporated into Multiplex Serology panels tailored for application in seroepidemiological studies. |
url |
https://doi.org/10.1371/journal.pone.0210407 |
work_keys_str_mv |
AT nicolebrenner validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT alexanderjmentzer validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT juliabutt validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT kathrinlbraband validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT angelikamichel validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT katiejeffery validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT paulklenerman validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT barbaragartner validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT paulschnitzler validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT adrianhill validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT grahamtaylor validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT mariaademontis validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT edwardguy validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT stephenjhadfield validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT rachaelalmond validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT naomiallen validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT michaelpawlita validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii AT timwaterboer validationofmultiplexserologyforhumanhepatitisvirusesbandchumantlymphotropicvirus1andtoxoplasmagondii |
_version_ |
1714819472894722048 |